替格瑞洛应用于急性冠状动脉综合征患者的临床有效性与安全性评价

摘要

目的：探讨替格瑞洛应用于急性冠状动脉综合征患者的临床有效性与安全性。方法60例急性冠状动脉综合征患者，随机分为试验组和对照组，各30例。对照组采取常规治疗，试验组在对照组基础上使用替格瑞洛治疗。比较两组患者的有效性和安全性。结果试验组不良事件总发生率6.67%低于对照组26.67%、服药后血小板抑制率(78.3±18.6)%优于对照组(64.3±7.4)%(P<0.05)。结论使用替格瑞洛应用于急性冠状动脉综合征临床效率高，有效性强，值得在临床推广。%ObjectiveTo investigate clinical effectiveness and safety by ticagrelor applied in patients with acute coronary syndrome.MethodsA total of 60 patients with acute coronary syndrome were randomly divided into experimental group and control group, with 30 cases in each group. The control group received conventional therapy, and the experimental group received additional ticagrelor for treatment. Comparison was made on effectiveness and safety between the two groups.ResultsThe experimental group had lower total incidence of adverse reactions as 6.67% than 26.67% in the control group, and its platelet inhibition ratio after medication was better as (78.3±18.6)% than (64.3±7.4)% in the control group (P<0.05).Conclusion Implement of ticagrelor contains high and precise effectiveness for acute coronary syndrome, and this method is worth clinical promoting.